Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
81 hedge funds and large institutions have $19.7M invested in Sio Gene Therapies Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 25 increasing their positions, 21 reducing their positions, and 33 closing their positions.
19% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 21
15% less call options, than puts
Call options by funds: $844K | Put options by funds: $989K
22% less funds holding
Funds holding: 104 → 81 (-23)
64% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 33
96% less capital invested
Capital invested by funds: $528M → $19.7M (-$509M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$3.46M |
| 2 |
Millennium Management
New York
|
+$1.7M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.15M |
| 4 |
Two Sigma Investments
New York
|
+$829K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$566K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QF
QVT Financial
New York
|
-$395M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$15M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12.8M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$5.92M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.64M |
SIOX Hedge Fund Activity: Q1 2018 in Review
81 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q1 2018, worth a combined $19.7M — down 96% from $528M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of SIOX and 12 opened new positions — a net loss of 21 holders — while 21 trimmed existing stakes and 25 added.
The largest buyer was Renaissance Technologies, adding an estimated $3.46M. The largest seller was QVT Financial, exiting entirely with an estimated $395M sold.
- 81 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q1 2018, down from 104 in Q4 2017.
- Funds reported $19.7M of Sio Gene Therapies Inc. Common Stock stock for Q1 2018, down 96% quarter-over-quarter.
- 12 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q1 2018 and 33 closed out, a net change of -21 holders.
- The largest Sio Gene Therapies Inc. Common Stock buyer in Q1 2018 was Renaissance Technologies, an estimated $3.46M added.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q1 2018 was QVT Financial, an estimated $395M sold.
Based on aggregated 13F filings for Q1 2018.